Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Lilly obesity-pill trial results find a warmer reception on Wall Street this time around
09:25am, Tuesday, 26'th Aug 2025
Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.
Eli Lilly's weight loss pill will likely be the market-leading product, says BofA's Tim Anderson
08:19am, Tuesday, 26'th Aug 2025
Tim Anderson, BofA Securities senior pharma analyst, joins 'Squawk Box' to discuss news of Eli Lilly's weight loss pill orforglipron clearing its latest trial, what it means for the drug going forward
Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals
07:34am, Tuesday, 26'th Aug 2025
Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.
Eli Lilly Says New Pill Results in 10.5% Weight-Loss for Diabetes Patients
06:50am, Tuesday, 26'th Aug 2025
Lilly said it's moving “with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting.”
Eli Lilly's weight loss pill orforglipron clears its latest trial, paving way for approval
06:45am, Tuesday, 26'th Aug 2025
Eli Lilly on Tuesday said its daily obesity pill succeeded in another late-stage trial, helping patients with obesity and Type 2 diabetes lose weight and lower their blood sugar levels. The company no
Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
09:00am, Monday, 25'th Aug 2025
INDIANAPOLIS , Aug. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, exe
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
08:00am, Monday, 25'th Aug 2025
- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE)
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
08:00am, Sunday, 24'th Aug 2025
Some analysts say Eli Lilly's daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors. In the trial
The Best Stocks to Invest $50,000 in Right Now
04:32am, Sunday, 24'th Aug 2025
Congratulations, you've got $50,000 in unexpected cash! Will you buy a new car?
Eli Lilly Vs. Novo Nordisk: One Stock Is Massively Undervalued, The Other Overvalued
08:55pm, Saturday, 23'rd Aug 2025
Novo Nordisk and Eli Lilly both declined significantly in the last months. This was mainly caused by efficacy uncertainty, further competition and political headwinds. Despite the sell-offs, I current
If I Could Only Buy 1 S&P 500 Stock From Each Sector for the Rest of 2025, I'd Go With These 11 Dividend Stocks
06:05pm, Saturday, 23'rd Aug 2025
The Global Industry Classification Standard assigns each stock into a market sector to make it easier for investors to compare companies to their peers and track broader market movements.
The Big 3: LLY, BA, CVS
12:01pm, Friday, 22'nd Aug 2025
Dan Deming considers Friday's trading action after Jerome Powell's Jackson Hole speech "remarkable." On stocks he's watching ahead, he expects Eli Lilly (LLY) to rebound off a significant sell-off, Bo
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 22'nd Aug 2025
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
09:50am, Friday, 22'nd Aug 2025
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
Lilly to participate in Wells Fargo 20th Annual Healthcare Conference
09:00am, Friday, 22'nd Aug 2025
INDIANAPOLIS , Aug. 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025. Patrik Jonsson, executive vice pre
